Aquila BioMedical Ltd., a preclinical contract research organization, has secured an extended agreement with biotech firm Macrophage Pharma Ltd., to support its preclinical immuno-oncology programs.

Macrophage Pharma’s immuno-oncology program with Aquila will incorporate a combination of types of analysis that include in vitro, in vivo and ex vivo. That will then generate data to make the choice of the best preclinical candidate for investigational new drug selection to enter Phase 1 clinical trials.

Clare Doris, chief operating officer at Aquila BioMedical said, “Previous work with Macrophage Pharma has established innovative and tailored biology solutions, producing high value mechanistic data that will help progress its promising molecules to the clinic.”